Sun Pharma launches cancer drug INFUGEM in US market

Sun Pharma said INFUGEM uses its proprietary technology which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers in ready-to-infuse final dosage bags.

New Delhi: Drug major Sun Pharmaceutical Industries Monday announced the launch of INFUGEM injection, used for the treatment of cancer, in the US market.

In July 2018, Sun Pharma had received approval from the US health regulator for the said injection.

Read Also: Sun Pharma gets one observation from USFDA for Baska plant

"INFUGEM (gemcitabine in sodium chloride injection), for intravenous use, is now commercially available in the US," Sun Pharma said in a regulatory filing.

"INFUGEM, the first chemotherapy product that comes in a premixed, ready-to-infuse formulation, was approved by the US Food and Drug Administration (USFDA) in July 2018 in combination with other drugs for the treatment of breast, ovarian, non-small cell lung cancers, and as a single agent for the treatment of pancreatic cancer," the company added.

Read Also: Setback to Sun Pharma: NPPA refuses to give relief of price cap exemption for Gemcitabine

Sun Pharma said INFUGEM uses its proprietary technology which allows cytotoxic oncology products to be premixed in a sterile environment and supplied to the prescribers in ready-to-infuse final dosage bags.

Read Also: NPPA fixes retail price of Sun Pharma Baclofen Oral Solution